BioVie Inc. (BIVI) Posts Phase 2 Subgroup Gains in Long COVID

BioVie Inc. reported that its experimental Parkinson's drug, bezisterim, improved motor and non-motor symptoms in early-stage patients with higher inflammation, according to Phase 2 SUNRISE-PD trial results. In the subgroup of 28 patients, those treated with bezisterim showed improvement, while placebo patients worsened slightly. Across all 57 patients, 25% on bezisterim saw meaningful improvement versus 4% on placebo.

BioVie Inc. (BIVI) reported Phase 2 trial results for bezisterim in early-stage Parkinson’s patients. In a subgroup with high inflammation, bezisterim improved motor and non-motor scores versus placebo. Overall, bezisterim patients were 6.25x more likely to show meaningful improvement. Adverse events were lower in the treatment group. The trial enrolled untreated patients using a hybrid design. BioVie focuses on neurological and liver disease therapies.

BioVie reported Phase 2 trial data showing bezisterim improved symptoms in Parkinson’s patients with higher platelet counts compared to placebo. Safety profiles were similar. The results were exploratory and require further Phase 3 trials for confirmation, according to the company.

BioVie Inc reported that its Phase 2 ADDRESS-LC trial showed bezisterim significantly improved fatigue, post-exertional malaise, and cognitive symptoms in Long COVID patients with severe baseline conditions. The trial, presented at the American Neurological Association’s meeting, involved 203 patients and showed improvements in multiple measures. Bezisterim had a safety profile comparable to placebo. The study was funded by the U.S. Department of War.

BioVie Inc (BIVI, BIVIW) will present Phase 2 trial results for its drug bezisterim in Long COVID and Parkinson's disease at the American Neurological Association meeting. The trials showed improvements in inflammation, biomarkers, and symptoms. Bezisterim is designed to reduce inflammation and improve insulin sensitivity. The company also has ongoing trials in Alzheimer's disease.

BioVie (NASDAQ:BIVI) will host an investor webinar on September 23, 2026, to discuss Phase 2 results of its drug bezisterim for Long COVID. CEO Cuong Do will present findings showing potential across key symptoms and discuss implications for neurological disorders. The company believes positive results could support bezisterim's development for multiple CNS conditions.